cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Anaptysbio Inc
4 own
5 watching
Current Price
$18.87
$-0.4
(-2.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
658.34M
52-Week High
52-Week High
27.50000
52-Week Low
52-Week Low
13.36000
Average Volume
Average Volume
0.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
121.2182
iconMarket Capitalization658.34M
icon52-Week High27.50000
icon52-Week Low13.36000
iconAverage Volume0.4M
iconDividend Yield--
iconP/E Ratio121.2182
What does the Anaptysbio Inc do?
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More
How much money does Anaptysbio Inc make?
News & Events about Anaptysbio Inc.
Globe Newswire
12 months ago
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab was generally safe and well tolerated with low overall ADA incidenceTop-line GEMINI-1 Phase 3 trial...
Ticker Report
1 year ago
AnaptysBio, Inc. (NASDAQ:ANAB Get Rating) Wedbush issued their Q1 2024 earnings estimates for shares of AnaptysBio in a report released on Thursday, March 2nd. Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($1.11) per share for the quarter. The ...
Globe Newswire
1 year ago
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up ...
Globe Newswire
1 year ago
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of...
Globe Newswire
1 year ago
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same ...
Frequently Asked Questions
Frequently Asked Questions
What is Anaptysbio Inc share price today?
plus_minus_icon
Can Indians buy Anaptysbio Inc shares?
plus_minus_icon
How can I buy Anaptysbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Anaptysbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Anaptysbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Anaptysbio Inc?
plus_minus_icon
What is today’s market capitalisation of Anaptysbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Anaptysbio Inc?
plus_minus_icon
What percentage is Anaptysbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Anaptysbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$18.87
$-0.4
(-2.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$9.83
$-0.32 (-3.15 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$12.36
$-1.39 (-10.11 %)
CABALETTA BIO INC
CABALETTA BIO INC
$12.18
$-0.78 (-6.02 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.59
$-0.16 (-1.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$9.83
$-0.32 (-3.15 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$12.36
$-1.39 (-10.11 %)
CABALETTA BIO INC
CABALETTA BIO INC
$12.18
$-0.78 (-6.02 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.59
$-0.16 (-1.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00